Does vaccination cause disease?;Machen impfungen krank?

Therapeutische Umschau

Volumn 62, Issue 10, 2005, Pages 665-674

  Zingg, Walter ^a  

^a Universitats Kinderklinik   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; THIOMERSAL; VACCINE;

ALLERGY; ASTHMA; ATAXIA; AUTISM; AUTOIMMUNITY; BACTERIAL INFECTION; CHICKENPOX; CHILD HEALTH CARE; CHRONIC ARTHRITIS; DIABETES MELLITUS; DIPHTHERIA; DRUG FORMULATION; DRUG SAFETY; EPIGLOTTITIS; FASCIITIS; GAIT DISORDER; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH EDUCATION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNIZATION; MEASLES; MENINGITIS; MULTIPLE SCLEROSIS; MUMPS; MYOSITIS; PARENT; POLIOMYELITIS; REVIEW; RUBELLA; SMALLPOX; TETANUS; VACCINATION; VIRUS INFECTION;

EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; MASS IMMUNIZATION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; VACCINATION; VACCINES;

EID: 27144451441     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.62.10.665     Document Type: Review

References (64)

1. Desgrandchamps D, Schmid R, Zimmermann HP, Imahorn P, Kabus K, Schubiger G. Effect of conjugated PRP vaccines on the incidence of invasive diseases caused by Haemophilus influenzae Type B in childhood. Schweiz Med Wochenschr 1994; 124: 575-82.
2. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991; 338: 1174-5.
3. Classen JB, Classen DC. Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM. Autoimmunity 2002; 35: 247-53.
4. Weibel RE, Benor DE. Chronic arthropathy and musculoskeletal symptoms associated with rubella vaccines. A review of 124 claims submitted to the National Vaccine Injury Compensation Program. Arthritis Rheum 1996; 39: 1529-34.
5. Shaheen SO, Aaby P, Hall AJ et al. Measles and atopy in Guinea-Bissau. Lancet 1996; 347: 1792-6.
6. Baker JP. The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine 2003; 21: 4003-10.
7. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001; 19: 4627-34.
8. Simonsen L, Morens D, Elixhauser A, Gerber M, Van Raden M, Blackwelder W. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 2001; 358: 1224-9.
9. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350: 896-903.
10. Zent O, Arras-Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations - a post-marketing surveillance review. Eur J Pediatr 2002; 161: 21-5.
11. Bohlke K, Davis RL, Marcy SM et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112: 815-20.
12. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103: 321-5.
13. Sakaguchi M, Inouye S. IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Vaccine 2000; 18: 2055-8.
14. James JM, Zeiger RS, Lester MR et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998; 133: 624-8.
15. The American Lung Association Asthma Clinical Research Centers. The Safety of Inactivated Influenza Vaccine in Adults and Children with Asthma. N Engl J Med 2001; 345: 1529-36.
16. Kemp T, Pearce N, Fitzharris P et al. Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology 1997; 8: 678-80.
17. Hurwitz EL, Morgenstern H. Effects of diphtheria-tetanus-pertussis or tetanus vaccination on allergies and allergy-related respiratory symptoms among children and adolescents in the United States. J Manipulative Physiol Ther 2000; 23: 81-90.
18. Nicolai T, Bellach B, Mutius EV, Thefeld W, Hoffmeister H. Increased prevalence of sensitization against aeroallergens in adults in West compared with East Germany. Clin Exp Allergy 1997; 27: 886-92.
19. Gruber C, Illi S, Lau S et al. MAS-90 Study Group. Transient suppression of atopy in early childhood is associated with high vaccination coverage. Pediatrics 2003; 111: e282-8.
20. Bager P, Westergaard T, Rostgaard K, Hjalgrim H, Melbye M. Age at childhood infections and risk of atopy. Thorax 2002; 57: 379-82.
21. Ronchi F, Cecchi P, Falcioni F et al. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch Dis Child 1998; 78: 273-4.
22. Neau D, Bonnet F, Michaud M et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand J Infect Dis 1998; 30: 115-8.
23. Ropper AH, Victor M. Influenza vaccination and the Guillain-Barre syndrome. N Engl J Med 1998; 339: 1845-6.
24. Haber P, DeStefano F, Angulo FJ et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004; 292: 2478-81.
25. Khamaisi M, Shoenfeld Y, Orbach H. Guillain-Barre syndrome following hepatitis B vaccination. Clin Exp Rheumatol 2004; 22: 767-70.
26. Tabor E. Guillain-Barre syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol 1987; 21: 207-16.
27. DeStefano F, Mullooly JP, Okoro CA et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001; 108: e112.
28. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004; 350: 1398-404.
29. Lindberg B, Ahlfors K, Carlsson A, et al. Previous exposure to measles, mumps, and rubella-but not vaccination during adolescence-correlates to the prevalence of pancreatic and thyroid autoantibodies. Pediatrics 1999; 104: e12.
30. Rewers M, Atkinson M. The possible role of enteroviruses in diabetes mellitus. In: Rotbart HA, ed. Human Enterovirus Infections. Washington, DC: American Society for Microbiology 1995: 353-85.
31. Clarkson TW. The toxicology of mercury. Crit Rev Clin Lab Sci 1997; 34: 369-403.
32. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001; 56: 462-71.
33. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001; 107: 1147-54.
34. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290: 1763-6.
35. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360: 1737-41.
36. Myers MG, Beckman CW, Vosdingh RA, Hankins WA. Primary immunization with tetanus and diphtheria toxoids. Reaction rates and immunogenicity in older children and adults. JAMA 1982; 248: 2478-80.
37. Beghi E, Kurland LT, Mulder DW, Nicolosi A. Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981. Ann Neurol 1985; 18: 320-3.
38. Pollard JD, Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci 1978; 37: 113-25.
39. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994; 271: 1602-5.
40. Mortimer J, Melville-Smith M, Sheffield F. Diphtheria vaccine for adults. Lancet 1986; 2: 1182-3.
41. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21: 2003-14.
42. Gold MS. Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern? Drug Saf 2002; 25: 85-90.
43. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against Pertussis after natural infection or vaccination. Ped Infect Dis J 2005; 24: s58-s61.
44. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002; 161: 142-6.
45. Christie CD, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children. N Engl J Med 1994; 331: 16-21.
46. Khetsuriani N, Bisgard K, Prevots DR et al. Pertussis out-break in an elementary school with high vaccination coverage. Pediatr Infect Dis J 2001; 20: 1108-12.
47. Bassinet L, Matrat M, Njamkepo E, Aberrane S, Housset B, Guiso N. Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol 2004; 25: 995-7.
48. MMWR Morb Mortal Wkly Rep 1998; 47: 737-40.
49. Rimaniol AC, Gras G, Verdier F et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004; 22: 3127-35.
50. Fawcett HA, Smith NP. Injection-site granuloma due to aluminum. Arch Dermatol 1984; 120: 1318-22.
51. Authier FJ, Cherin P, Creange A et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001; 124: 974-83.
52. Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 2005; 23: 1359-67.
53. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001; 107: e83.
54. Fourrier A, Begaud B, Alperovitch A et al. Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases. Br J Clin Pharmacol 2001; 51: 489-90.
55. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-32.
56. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000; 355: 549-50.
57. Confavreux C, Suissa S, Saddier P et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344: 319-26.
58. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004; 63: 838-42.
59. Demicheli V, Rivetti A, Di Pietrantonj C, Clements CJ, Jefferson T. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat 2003; 10: 343-1.
60. Ray P, Black S, Shinefield H et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278: 551-6.
61. Pool V, Braun MM, Kelso JM et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics 2002; 110: e71.
62. Committee on Infectious Diseases. 2003 Red Book - report of the Committee on Infectious Diseases. 26th ed. Elk Grove (IL): American Academy of Pediatrics; 2003.
63. Plesner AM. Gait disturbances after measles, mumps, and rubella vaccine. Lancet 1995; 345: 316.
64. Miller E, Andrews N, Grant A, Stowe J, Taylor B. No evidence of an association between MMR vaccine and gait disturbance. Arch Dis Child 2005; 90: 292-6.